{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:02:56Z","timestamp":1780588976979,"version":"3.54.1"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Drug shortages are an ongoing challenge in health care delivery. Research has focused on factors associated with manufacturer-level shortage reports; however, these reports do not reflect population-level drug availability. It is essential to determine the impact of supply chain events on trends in drug utilization and identify factors associated with decreases in use to ascertain shortage risk and inform future policy prioritization.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To quantify incident shortages following Canadian supply chain events and determine drug characteristics associated with increased shortage risk.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This matched cohort study analyzed monthly trends in drug purchasing of Canadian pharmaceutical products from the IQVIA MIDAS database from January 2017 to December 2021 with a 6-month follow-up. Data were analyzed from September 2023 to September 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Reporting of a supply chain issue in Drug Shortages Canada.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was an incident shortage, defined as a decrease of 33% or more in purchase volume within 6 months following the supply chain issue. A logistic regression with random effects compared the odds of experiencing an incident shortage for cases and controls. A secondary outcome, shortage intensity, defined as the decrease in purchases multiplied by the duration, was analyzed using a zero-inflated beta regression with random effects.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 1591 drugs, 972 unique drugs (61%) were exposed to 1919 supply chain events. Incident shortages were observed in 11% of cases (216 drugs), compared with 7% of controls (1271 comparators). Drugs with baseline sales less than $100\u202f000 (odds ratio [OR], 4.01; 95% CI, 3.03-5.30), anti-infective drugs (OR, 3.07; 95% CI, 2.33-4.04), and over-the-counter drugs (OR, 3.05; 95% CI, 2.38-3.90) had greater odds of experiencing an incident shortage. Schedule G drugs, which include controlled drugs (OR, 3.61; 95% CI, 1.66-7.77), drugs with more than 25 unique products available (OR, 2.86; 95% CI, 1.89-4.44), and those with equal dominance in both retail and hospital sectors (OR, 2.43; 95% CI, 1.93-3.01) had the largest magnitudes of association with higher shortage intensity.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study of shortage incidence following Canadian supply chain events, 9 in 10 reported supply chain events did not experience true shortages. These findings highlight a need for a unified shortage definition focusing on real disruptions in supply and can be used to guide policies to manage drug shortages, improve patient outcomes, and enhance health care delivery.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.16632","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:30:31Z","timestamp":1780587031000},"page":"e2616632","source":"Crossref","is-referenced-by-count":0,"title":["Supply Chain Events and Risk of Drug Shortage in Canada"],"prefix":"10.1001","volume":"9","author":[{"given":"Araniy","family":"Santhireswaran","sequence":"first","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin K. H.","family":"Ho","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine Callaway","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzeh","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J.","family":"Suda","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"},{"name":"Center for Healthcare Evaluation, Research, and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Gaudette","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Burry","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada"},{"name":"Sinai Health and Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada"},{"name":"Women\u2019s College Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"23","key":"zoi260469r2","doi-asserted-by":"publisher","first-page":"E801","DOI":"10.1503\/cmaj.212070","article-title":"COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022.","volume":"194","author":"Lau","year":"2022","journal-title":"CMAJ"},{"key":"zoi260469r5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.693426","article-title":"Drug shortage: causes, impact, and mitigation strategies.","volume":"12","author":"Shukar","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"zoi260469r6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.sapharm.2025.10.008","article-title":"Causes and management of drug shortages: a scoping review.","volume":"22","author":"Cornelissen","year":"2026","journal-title":"Res Social Adm Pharm"},{"issue":"5","key":"zoi260469r7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/CIRCULATIONAHA.119.044494","article-title":"Population impact of generic Valsartan recall.","volume":"141","author":"Jackevicius","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"zoi260469r8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jemermed.2017.07.012","article-title":"Association between U.S. norepinephrine shortage and mortality among patients with septic shock.","volume":"53","author":"Vail","year":"2017","journal-title":"J Emerg Med"},{"issue":"8","key":"zoi260469r9","doi-asserted-by":"publisher","first-page":"e1289","DOI":"10.1200\/OP.21.00883","article-title":"National survey on the effect of oncology drug shortages in clinical practice: a Hematology Oncology Pharmacy Association Survey.","volume":"18","author":"McBride","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"12","key":"zoi260469r12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293497","article-title":"Early observations of tier-3 drug shortages on purchasing trends across Canada: a cross-sectional analysis of 3 case-example drugs.","volume":"18","author":"Santhireswaran","year":"2023","journal-title":"PLoS One"},{"key":"zoi260469r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109705","article-title":"Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.","volume":"242","author":"Konstantelos","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"zoi260469r16","doi-asserted-by":"publisher","first-page":"E535","DOI":"10.9778\/cmajo.20200036","article-title":"Factors associated with drug shortages in Canada: a retrospective cohort study.","volume":"8","author":"Zhang","year":"2020","journal-title":"CMAJ Open"},{"issue":"3","key":"zoi260469r17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.pharma.2018.11.007","article-title":"Drug shortages in Canada: data for 2016-2017 and perspectives on the problem.","volume":"77","author":"Videau","year":"2019","journal-title":"Ann Pharm Fr"},{"issue":"3","key":"zoi260469r18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.pharma.2024.12.001","article-title":"Drug shortages in Canada, 2019-2023: a descriptive study.","volume":"83","author":"B\u00e9atrix","year":"2025","journal-title":"Ann Pharm Fr"},{"issue":"4","key":"zoi260469r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.4246","article-title":"Drug shortages prior to and during the COVID-19 pandemic.","volume":"7","author":"Callaway Kim","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi260469r24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3414\/ME9241","article-title":"Efficient risk set sampling when a time-dependent exposure is present: matching for time to exposure versus exposure density sampling.","volume":"48","author":"Wolkewitz","year":"2009","journal-title":"Methods Inf Med"},{"issue":"22","key":"zoi260469r25","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1002\/sim.8305","article-title":"Exposure density sampling: dynamic matching with respect to a time-dependent exposure.","volume":"38","author":"Ohneberg","year":"2019","journal-title":"Stat Med"},{"issue":"3","key":"zoi260469r26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/ije\/dyr041","article-title":"The Simpson\u2019s paradox unraveled.","volume":"40","author":"Hern\u00e1n","year":"2011","journal-title":"Int J Epidemiol"},{"key":"zoi260469r27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2288-14-83","article-title":"Matching methods to create paired survival data based on an exposure occurring over time: a simulation study with application to breast cancer.","volume":"14","author":"Savignoni","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"zoi260469r28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/cid\/cix379","article-title":"The effect of a piperacillin\/tazobactam shortage on antimicrobial prescribing and clostridium difficile risk in 88 US medical centers.","volume":"65","author":"Gross","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"22","key":"zoi260469r29","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1001\/jama.2024.17688","article-title":"Differences in drug shortages in the US and Canada.","volume":"332","author":"Tadrous","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"zoi260469r30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2025-018960","article-title":"The association between drug shortages and prices across 74 countries: uncovering global access inequities.","volume":"10","author":"Hu","year":"2025","journal-title":"BMJ Glob Health"},{"issue":"1","key":"zoi260469r31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13253-022-00516-z","article-title":"Zero-inflated beta distribution regression modeling.","volume":"28","author":"Tang","year":"2023","journal-title":"J Agric Biol Environ Stat"},{"issue":"3","key":"zoi260469r35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/BF02294361","article-title":"Model selection and Akaike\u2019s information criterion (AIC): the general theory and its analytical extensions.","volume":"52","author":"Bozdogan","year":"1987","journal-title":"Psychometrika"},{"issue":"2","key":"zoi260469r36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v034.i02","article-title":"Beta regression in R.","volume":"34","author":"Cribari-Neto","year":"2010","journal-title":"J Stat Softw"},{"issue":"1","key":"zoi260469r37","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1186\/s12913-022-08309-3","article-title":"National and transnational drug shortages: a quantitative descriptive study of public registers in Europe and the USA.","volume":"22","author":"Ravela","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"zoi260469r38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1017\/jme.2024.105","article-title":"Comparative analysis of drug shortages in the US and Germany (2016-2023).","volume":"52","author":"Nussli","year":"2024","journal-title":"J Law Med Ethics"},{"issue":"1","key":"zoi260469r40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40545-022-00439-7","article-title":"Drug shortages in low- and middle-income countries: Colombia as a case study.","volume":"15","author":"Sabogal De La Pava","year":"2022","journal-title":"J Pharm Policy Pract"},{"issue":"7","key":"zoi260469r41","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70178","article-title":"Impact of supply chain disruptions and drug shortages on drug utilization: a scoping review.","volume":"34","author":"Santhireswaran","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi260469r34","first-page":"215","volume-title":"Selected Papers of Hirotugu Akaike","author":"Akaike","year":"1998"},{"key":"zoi260469r1","unstructured":"American Society of Health-System Pharmacists (ASHP). Drug shortages statistics. Accessed April 23, 2026. https:\/\/www.ashp.org\/drug-shortages\/shortage-resources\/drug-shortages-statistics?loginreturnUrl=SSOCheckOnly"},{"key":"zoi260469r3","unstructured":"World Health Organization. Shortages impacting access to glucagon-like peptide 1 receptor agonist products; increasing the potential for falsified versions. Published January 29, 2024. Accessed May 28, 2024. https:\/\/www.who.int\/news\/item\/29-01-2024-shortages-impacting-access-to-glucagon-like-peptide-1-receptor-agonist-products--increasing-the-potential-for-falsified-versions"},{"key":"zoi260469r4","unstructured":"Health Canada. Tier 3 drug shortages. Updated April 22, 2026. Accessed April 23, 2026. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-shortages\/tier-3-shortages.html"},{"key":"zoi260469r10","unstructured":"Health Canada. Guide to the exceptional importation and sale of drugs in response to drug shortages (GUI-0148). Government of Canada. Updated April 19, 2025. Accessed April 23, 2026. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/drugs-health-products\/guide-exceptional-import-sale-response-drug-shortages.html"},{"key":"zoi260469r11","unstructured":"Health Canada. Stockpiling drugs can lead to local shortages: Canadians urged not to buy more medication than usual during the COVID-19 pandemic. Government of Canada. Published March 30, 2020. Updated June 15, 2020. Accessed April 23, 2026. https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/stockpiling-drugs-can-lead-local-shortages-canadians-urged-not-buy-more-medication"},{"key":"zoi260469r14","unstructured":"Health Canada. Mandatory reporting of drug shortages and discontinuations. Government of Canada. Updated March 19, 2025. Accessed April 23, 2026. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-shortages\/regulations-guidance.html#a2"},{"key":"zoi260469r15","unstructured":"Health Canada. Guide to reporting drug shortages and discontinuations. Updated March 20, 2025. Accessed April 23, 2026. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/drugs-health-products\/reporting-drug-shortages-discontinuations.html"},{"key":"zoi260469r20","unstructured":"Government of Canada. Tri-Council policy statement: ethical conduct for research involving humans\u2014TCPS 2 (2022). Accessed April 28, 2026. https:\/\/ethics.gc.ca\/eng\/policy-politique_tcps2-eptc2_2022.html"},{"key":"zoi260469r21","unstructured":"IQVIA. Available IQVIA data. Accessed October 4, 2022. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/available-iqvia-data"},{"key":"zoi260469r22","unstructured":"IQVIA. 2022 ACTS annual report: statistical quality assurance applied to IQVIA\u2019s Information offerings. Accessed November 10, 2024. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/publications\/2022-acts-annual-report.pdf"},{"key":"zoi260469r23","unstructured":"Health Product Shortages Canada. Accessed April 23, 2026. https:\/\/healthproductshortages.ca\/"},{"key":"zoi260469r32","unstructured":"World Health Organization. WHO model list of essential medicines\u201423rd list, 2023. Published July 26, 2023. Accessed April 23, 2026. https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02"},{"key":"zoi260469r33","unstructured":"Ontario Ministry of Health. Ontario drug benefit formulary search. Accessed April 23, 2026. https:\/\/www.formulary.health.gov.on.ca\/formulary\/"},{"key":"zoi260469r39","unstructured":"Eastern Research Group Inc. Analysis of drug shortages, 2018-2023. Office of the Assistant Secretary for Planning and Evaluation. Published January 14, 2025. Accessed April 23, 2026. https:\/\/aspe.hhs.gov\/reports\/drug-shortages-2018-2023"},{"key":"zoi260469r42","unstructured":"Patented Medicine Prices Review Board. Drug shortages in Canada and their impact on public drug plans. Accessed November 10, 2023. http:\/\/www.pmprb-cepmb.gc.ca\/CMFiles\/NPDUIS\/refdocs\/Reference%20Doc_NPDUIS%20Source%20Materials_EN.pdf"},{"key":"zoi260469r43","unstructured":"Health Canada. Health Canada\u2019s critical and vulnerable drug list. Government of Canada. Updated April 13, 2026. Accessed April 23, 2026. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-shortages\/critical-vulnerable-list.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849877\/santhireswaran_2026_oi_260469_1779986530.90991.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:30:41Z","timestamp":1780587041000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.16632","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}